Business Wire

RESORTTRUST

23.9.2020 07:22:22 CEST | Business Wire | Press release

Share
The Kahala Hotel & Resort Yokohama to Open

Resorttrust, Inc. (TOKYO:4681) has announced that The Kahala Hotel & Resort Yokohama will open for business on September 23.

One of the most famous hotels in Honolulu, The Kahala Hotel & Resort, has continued to be a favorite destination of guests from around the world for more than half a century. The Kahala Hotel & Resort Yokohama represents a first step toward growing the Kahala brand worldwide.

Yokohama, at just 30 minutes by car from Haneda Airport, is very conveniently located, and is a community rich in history and with a unique culture. It is also considered to be an up and coming global city.

But there are also perfectly appropriate reasons for Yokohama to be the first place in Japan to open a Hawaiian hotel brand. In 1868, Japan’s first emigrants set off from the Osanbashi area in Yokohama to what was then the new paradise known as Hawaii. Some decades later, it was also Yokohama where the Meiji government in Japan welcomed its first state guest, King David Kalakaua from the Kingdom of Hawaii. Building on the connections between Yokohama and Hawaii, and embodying a spirit of aloha, The Kahala Hotel & Resort Yokohama will carry on the Hawaiian hospitality tradition, and looks forward to welcoming guests as ohana , the Hawaiian concept that includes both family and treasured friends.

Every effort was made to adhere to the philosophy of the Spirit of Kahala, which has carefully cultivated the Kahala brand since The Kahala was opened in Hawaii’s Kahala region 56 years ago. A new Kahala story, with a wide diversity of faces, will therefore be offered to everyone from Yokohama as well.

NOTE: The Spirit of Kahala, an offshoot of the spirit of aloha, is the source for the Kahala brand. It shows profound respect for the lives, culture, and traditions of local peoples.

Overview

Opening Date: September 23, 2020
Name: The Kahala Hotel & Resort Yokohama
Address: 1-1-3 Minato Mirai, Nishi Ward, Yokohama City, Kanagawa Prefecture
Access: Approximately eight minutes on foot from either Shintakashima or Minatomirai stations on the Minato Mirai Line, approximately six minutes by taxi from Yokohama Station on the Tokaido Line, or approximately 20 minutes from Shinyokohama Station on Tokaido Shinkansen Line.

Website: https://thekahala.jp/yokohama/
Official Facebook site: facebook.com/thekahalahotelandresortyokohama/
Official Instagram account: instagram.com/kahalaresort_yokohama

Link:

ClickThru

Social Media:

https://www.facebook.com/thekahalahotelandresortyokohama/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Inspirit Capital to Acquire Kaplan Languages Group20.4.2026 17:15:00 CEST | Press release

Inspirit Capital, a specialist investor in corporate carve-outs, is pleased to announce its plans to acquire KLG Kaplan Languages Group (“KLG”), a leading global language education platform, from Kaplan. All conditions for the sale have been met, and completion is due to take place on 1 May. KLG comprises Kaplan International Languages, Alpadia Language Schools, Azurlingua, and ESL Education. Since 2006, KLG has provided high-quality language education, supporting students in achieving their language goals through academic excellence, cultural immersion, and life-changing experiences. Inspirit Capital will support KLG in delivering on its ambitious growth plans, whilst continuing its fundamental mission to transform lives through language education. This next phase of ownership will also see the development of a refreshed standalone brand identity for KLG, with further announcements to follow on this in due course. Paul Youens, Investment Director, Inspirit Capital: “KLG has built a st

Cleaner by Design: SaniSure Introduces PETG PharmaTainer™ Ultra-Clean Bottles & Carboys20.4.2026 16:00:00 CEST | Press release

Industry’s most widely adopted PETG material meets industry-leading cleanliness, compliance, and RNase/DNase-free validation—now available across the full bioprocessing workflow. SaniSure® today announced the launch of PETG PharmaTainer™, a new line of bioprocessing bottles and carboys combining widely accepted, medical-grade Eastman Eastar® PETG 6763 resin (DMF#9987) with SaniSure’s proprietary process and advanced automation. This launch expands SaniSure’s established PharmaTainer® platform—extending its proven cleanliness, robustness, and performance attributes to include industry-standard PETG alongside its existing PET and PC offerings. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260420641769/en/ PETG PharmaTainer™ bottles and carboys—RNase/DNase-free, ultra-clean, ready-to-use containers for bioprocessing applications. Available in volumes from 10 mL stability vials to 10 L carboys — in sterile (gamma-irradiated) an

Leaders of Dubai-Based Unicorns Hail City as Global Innovation Hub Shaping Future Technology and Driving the Digital Economy20.4.2026 15:08:00 CEST | Press release

Leaders of Dubai-based unicorn companies have reaffirmed the emirate’s status as a global hub for digital innovation and technology-led growth. The senior executives highlighted Dubai’s forward-looking regulatory environment, advanced infrastructure, and ability to attract international talent as key factors strengthening its appeal for high-growth digital businesses. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260420503062/en/ Leaders of Dubai-based unicorns hail city as global innovation hub shaping future technology and driving the digital economy (Photo: AETOSWire) They noted that Dubai has evolved into a strategic launchpad for ambitious companies, offering an agile business environment that supports innovation and enables expansion into regional and international markets. The business leaders also praised the strong alignment between the public and private sectors within Dubai’s digital ecosystem, supported by Dubai

Capcom’s All-New IP PRAGMATA Surpasses One Million Units Sold in Two Days!20.4.2026 15:00:00 CEST | Press release

– Highly innovative and original gameplay earns strong reception from players around the globe – Capcom Co., Ltd. (TOKYO:9697) today announced that worldwide sales of PRAGMATA, the company’s all-new IP released on April 17, 2026*, have surpassed one million units. PRAGMATA is a science-fiction action-adventure game that depicts the journey of Hugh Williams and Diana, an android girl, in a near-future lunar world. A completely new IP, PRAGMATA was developed primarily by a team of younger Capcom developers, who created an innovative gameplay experience by fusing action gameplay with puzzle elements set within a distinctive world ruled over by artificial intelligence. In the absence of an established fan base or preexisting brand recognition, Capcom implemented a range of marketing initiatives—beginning with the early release of a playable demo—to communicate the unique features of the game to a wider audience. In addition, in line with the company’s multi-platform strategy, Capcom broade

Following Oral Presentation of Phase I Data at AACR 2026, Debiopharm Announces FDA Fast Track Designation for Lunresertib in Combination With Zedoresertib for Genomic-Defined Platinum-Resistant Ovarian Cancer20.4.2026 14:30:00 CEST | Press release

Debiopharm (www.debiopharm.com), a privately-owned, Swiss-based biopharmaceutical company aiming to establish tomorrow’s standard of care to cure cancer and infectious diseases, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to the combination of its PKMYT1 inhibitor, lunresertib (Debio2513), and its WEE1 inhibitor, zedoresertib (Debio 0123). The designation is for the treatment of adult patients with CCNE1 amplified, or a deleterious mutation in either FBXW7 or PPP2R1A, platinum-resistant/refractory ovarian cancer. The FDA’s Fast Track program is designed to facilitate the development and expedite the review of new drugs intended to treat serious conditions and fill an unmet medical need. Programs granted Fast Track designation benefit from more frequent communication with the FDA and, if relevant criteria are met, may be eligible for Priority Review and Accelerated Approval of a New Drug Application (NDA). Momentum Following AACR O

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye